Partnership Expands Reach of C2N's PrecivityTM Blood Tests in Over 75 Countries to Transform Alzheimer's Disease Early Diagnosis and Research Agreement Plans to Facilitate a Technology Transfer of C2N's Proprietary Portfolio of Alzheimer's Blood Biomarkers to Deliver a Unilabs Testing Network Across Europe ST. LOUIS , Miss. and GENEVA, SWITZERLAND , Aug.
7, 2024 /PRNewswire/ -- Unilabs ("Unilabs"), a leading international provider of diagnostic services, and C2N Diagnostics , LLC ("C2N"), a pioneer in advanced diagnostic solutions in the field of Alzheimer's disease (AD) and related neurological disorders, today announced a major milestone in brain health diagnostics and research across Europe and beyond. Unilabs and C2N have signed a multi-year partnership agreement that will increase access to C2N's Precivity portfolio of blood tests on an exclusive basis in Europe , including Norway , Switzerland , and the United Kingdom . The agreement will also provide access in Peru , Saudi Arabia , and the United Arab Emirates .
"Alzheimer's disease is on the rise, making it essential to innovate by offering less invasive and more accessible diagnostic procedures for patients," said Unilabs' Head of Innovation Dr. Rahul Chaudhary . "All too often, diagnosing Alzheimer's has been painful, invasive and expensive.
This partnership will transform the diagnostic experience for patients with cognitive concerns while revolutionizing early diagnosis, and research efforts, and positively impact.